CClinicalTrials.gg
CompletedNCT03154268GWGCPWUpdated May 16, 2017

Retrospective Longitudinal Study of Gestational Weight Gain Among Chinese Pregnant Women

An observational study in Gestational Weight Gain, sponsored by West China Hospital. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2017-05-16.

Sponsored by West China Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,422
Sex
Female
01

Study summary

The purpose of this study is to investigate the reference ranges and rates of gestational weight gain among Chinese pregnant women, and to analyze the correlation between gestational weight gain and adverse outcomes.

02

Conditions studied

  • Gestational Weight Gain

Keywords

  • Gestational weight gain
  • Chinese pregnant women
  • Retrospective longitudinal study
  • China
  • IOM guideline
  • Adverse outcome
  • Model
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's enrollment of 10,422 is above the median of 140 across 238 observational studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese pregnant women who had deliveries at West China Women and Children's Hospital, Sichuan University

Eligibility criteria

Inclusion Criteria:

  1. Deliveries between January 2013 and December 2014;
  2. Gestational age between 37 weeks or older and less than 42 weeks;
  3. Registration with care documents at the first prenatal visit prior to the 15th gestational week;
  4. Had at least five follow-up visits until delivery.

Exclusion Criteria: None

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,422 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Preeclampsia

    Maternal systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg during gestation. Urine protein ≥5.0 g within 24h, urine volume \<400 mL. HELLP syndrome or pulmonary edema present.

    Time frame: After 20th gestational weeks till delivery, about 5 months

  2. Eclampsia

    Tonic-clonic seizures (convulsions) in preeclampsia patients, including convulsions and coma, not due to pre-existing or organic brain disorders.

    Time frame: After 20th gestational weeks till delivery, about 5 months

  3. ICP

    Intrahepatic cholestasis of pregnancy.

    Time frame: After 14th gestational weeks till delivery, about 6 months

  4. Placenta previa

    Placenta partially or entirely covered the lower uterine segment diagnosed using antenatal ultrasound.

    Time frame: During pregnancy till delivery

  5. Gestational diabetes

    By oral glucose tolerance test between 24th and 28th gestational weeks (fasting glucose ≥5.1 mmol/L, 1-h glucose ≥10.0 mmol/L, 2-h glucose ≥8.5 mmol/L; one abnormal result sufficient).

    Time frame: After 24th gestational weeks, about 4 months

  6. Ruptured uterus

    Rupture of maternal uterus confirmed by laparotomy.

    Time frame: During delivery

  7. Placental abruption

    Abruption of a normally positioned placenta before delivery, diagnosed by clinical symptoms, ultrasound, fetal heart monitoring, or laboratory tests.

    Time frame: After 20th gestational weeks till delivery, about 5 months

  8. Postpartum hemorrhage

    Postpartum bleeding volume ≥500 mL.

    Time frame: Within 24h after delivery

  9. Hepatic diseases

    Hepatitis-B/C/E virus infection, acute fatty liver disease, or severe hepatitis.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  10. Hematological diseases

    Iron-deficiency anemia, thalassemia, hemophilia, idiopathic thrombocytopenic purpura, aplastic anemia, or disseminated intravascular coagulation.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  11. Gynecological diseases

    Uterine fibroids, ovarian cyst, cervical carcinoma, pelvic inflammation, or ovarian carcinoma.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  12. Respiratory diseases

    Pneumonia, bronchitis, asthma or pulmonary tuberculosis.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  13. Thyroid disease

    Hyperthyroidism or hypothyroidism.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  14. ICU admission

    Admission to intensive care unit.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  15. Maternal death

    Maternal death.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  16. Macrosomia

    Birth weight \>4000 g.

    Time frame: within 1 month after delivery

  17. Infant of low-birth weight

    Birth weight \<2500 g.

    Time frame: within 1 month after delivery

  18. Neonatal ICU admission

    Admission to neonatal intensive care unit.

    Time frame: Within 1 month after delivery

  19. Neonatal death

    Neonatal death.

    Time frame: Within 1 month after delivery

  20. Large for gestational age

    Neonatal weight, length, or head circumference above the 90th percentile for that gestational age.

    Time frame: Within 1 month after delivery

  21. Small for gestational age

    Neonatal weight, length, or head circumference below the 10th percentile for that gestational age.

    Time frame: Within 1 month after delivery

  22. Neonatal defect

    Neonatal defect.

    Time frame: Within 1 month after delivery

  23. Maternal adverse outcomes

    There occurred one or more of preeclampsia, eclampsia, ICP, placenta previa, gestational diabetes, ruptured uterus, placental abruption, postpartum hemorrhage, hepatic diseases, hematological diseases, gynecological diseases, respiratory diseases, thyroid disease, ICU admission, or maternal death.

    Time frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year

  24. Neonatal adverse outcomes

    There occurred one or more of macrosomia, low-birth weight, neonatal ICU admission, neonatal death, large for gestational age, small for gestational age, or neonatal defect.

    Time frame: Within 1 month after delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03154268
Lead sponsor
West China Hospital
Collaborators
West China Second University Hospital
Responsible party
Jing Tan (Chinese Evidence-based Medicine Center, West China Hospital) — Principal investigator
First posted
May 16, 2017
Start date
Jan 2015
Primary completion
Dec 2016
Completion
Mar 2017
Last update
May 16, 2017

Study contacts

Xin Sun, Doctor
principal investigator · Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion